Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis
- PMID: 9739110
- DOI: 10.1016/s0006-8993(98)00720-3
Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: a consideration of dose, core temperature and dopamine synthesis
Abstract
Amphetamine releases dopamine through a transporter-mediated mechanism. The purpose of this report was to further our understanding of the intracellular pool from which amphetamine releases dopamine: the cytoplasmic pool, the vesicular pool, or both. Rats were treated with D-amphetamine (AMPH) (1.0 or 10.0 mg/kg) or an amphetamine analog, methylenedioxymethamphetamine (MDMA) (2.0, 5.0, or 10.0 mg/kg). Pre-treatment with 10.0 mg/kg reserpine (18 h prior to AMPH or MDMA) attenuated dopamine release for high and low AMPH doses; however the low-dose effect showed borderline significance. Pre-treatment with 10.0 mg/kg reserpine attenuated dopamine and serotonin release induced by MDMA. The dopamine effect was seen at all three MDMA doses; the effect on serotonin was only measured at the 10.0 mg/kg dose. Reserpine pre-treatment caused reductions in core body temperature; heating the rats to normal body temperature for 3 h prior to AMPH or MDMA, and during the 4 h post-treatment period partially reversed the reserpine-induced attenuation of dopamine release. However, the intermediate level of dopamine release for the reserpinized-heated animals was not significantly different from either the reserpine group (not heated) or the AMPH or MDMA alone groups. In a separate group of rats, the effects of reserpine and reserpine+heat on dopamine synthesis were measured. DOPA accumulation after treatment with the aromatic acid decarboxylase inhibitor NSD-1015 (100 mg/kg, 30 min before sacrifice), was greater in rats treated with reserpine compared to controls; heating the reserpinized rats did not significantly alter the amount of DOPA accumulation; however there was a trend towards further increase. These results suggest that D-amphetamine releases dopamine that is stored in both vesicles and the cytoplasm. Cooling may contribute to the attenuation of AMPH or MDMA-induced dopamine release observed after reserpine; however, AMPH or MDMA dependence upon vesicular stores most likely explains the diminished release after reserpine. The attenuation of AMPH or MDMA-induced transmitter release by reserpine is thought to be counteracted by a reserpine-induced replenishment of stores. Therefore, all doses of D-amphetamine may use vesicular stores; the degree to which new synthesis counteracts the vesicular depletion may be the variable which differentiates low from high doses of D-amphetamine.
Copyright 1998 Elsevier Science B.V.
Similar articles
-
Effects of d-amphetamine and dopamine synthesis inhibitors on dopamine and acetylcholine neurotransmission in the striatum. I. Release in the absence of vesicular transmitter stores.J Pharmacol Exp Ther. 1986 Apr;237(1):179-92. J Pharmacol Exp Ther. 1986. PMID: 3007736
-
Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices.Naunyn Schmiedebergs Arch Pharmacol. 1993 Mar;347(3):313-23. doi: 10.1007/BF00167451. Naunyn Schmiedebergs Arch Pharmacol. 1993. PMID: 8097569
-
[3H]Dopamine release by d-amphetamine from striatal synaptosomes of reserpinized rats.Biochem Pharmacol. 1982 Jun 1;31(11):1969-74. doi: 10.1016/0006-2952(82)90406-3. Biochem Pharmacol. 1982. PMID: 7115417
-
3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.J Pharmacol Exp Ther. 2001 Jun;297(3):846-52. J Pharmacol Exp Ther. 2001. PMID: 11356903 Review.
-
Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse.J Neurochem. 2021 Jun;157(5):1714-1724. doi: 10.1111/jnc.15348. Epub 2021 Mar 25. J Neurochem. 2021. PMID: 33711169 Review.
Cited by
-
Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.Psychopharmacology (Berl). 2004 May;173(3-4):249-63. doi: 10.1007/s00213-004-1788-8. Epub 2004 Apr 9. Psychopharmacology (Berl). 2004. PMID: 15083264 Review.
-
Sex and strain differences in dynamic and static properties of the mesolimbic dopamine system.Neuropsychopharmacology. 2020 Nov;45(12):2079-2086. doi: 10.1038/s41386-020-0765-1. Epub 2020 Jul 14. Neuropsychopharmacology. 2020. PMID: 32663840 Free PMC article.
-
Cocaine self-administration produces pharmacodynamic tolerance: differential effects on the potency of dopamine transporter blockers, releasers, and methylphenidate.Neuropsychopharmacology. 2012 Jun;37(7):1708-16. doi: 10.1038/npp.2012.17. Epub 2012 Mar 7. Neuropsychopharmacology. 2012. PMID: 22395730 Free PMC article.
-
3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats.Physiol Behav. 2019 Feb 1;199:343-350. doi: 10.1016/j.physbeh.2018.12.007. Epub 2018 Dec 4. Physiol Behav. 2019. PMID: 30529341 Free PMC article.
-
Preliminary Results on the Long-Term Effects of Dextromethorphan on MDMA-Mediated Serotonergic Deficiency and Volumetric Changes in Primates Based on 4-[18F]-ADAM PET/MRI.Front Neurosci. 2022 May 19;16:837194. doi: 10.3389/fnins.2022.837194. eCollection 2022. Front Neurosci. 2022. PMID: 35692422 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical